EC Number |
Recommended Name |
Source Tissue |
Reference |
---|
1.1.1.146 | 11beta-hydroxysteroid dehydrogenase |
DU-145 cell |
- |
760802 |
1.1.1.188 | prostaglandin-F synthase |
DU-145 cell |
- |
741088 |
1.1.1.205 | IMP dehydrogenase |
DU-145 cell |
- |
761611 |
1.1.1.27 | L-lactate dehydrogenase |
DU-145 cell |
lactate dehydrogenase-B is silenced by promoter hypermethylation in human prostate cancer |
670443 |
1.1.1.357 | 3alpha-hydroxysteroid 3-dehydrogenase |
DU-145 cell |
- |
740737 |
1.1.1.8 | glycerol-3-phosphate dehydrogenase (NAD+) |
DU-145 cell |
mGPDH abundance and activity is significantly elevated in prostate cancer cell lines when compared to the normal prostate epithelial cell line PNT1A |
667415 |
1.13.11.34 | arachidonate 5-lipoxygenase |
DU-145 cell |
- |
688104 |
1.13.11.71 | carotenoid-9',10'-cleaving dioxygenase |
DU-145 cell |
- |
745753 |
1.14.11.16 | peptide-aspartate beta-dioxygenase |
DU-145 cell |
- |
764407 |
1.14.11.54 | mRNA N1-methyladenine demethylase |
DU-145 cell |
- |
742749, 765483 |
1.14.11.65 | [histone H3]-dimethyl-L-lysine9 demethylase |
DU-145 cell |
- |
754938 |
1.14.11.67 | [histone H3]-trimethyl-L-lysine4 demethylase |
DU-145 cell |
- |
744413 |
1.14.14.19 | steroid 17alpha-monooxygenase |
DU-145 cell |
- |
694117 |
1.14.14.32 | 17alpha-hydroxyprogesterone deacetylase |
DU-145 cell |
- |
694117 |
1.14.15.18 | calcidiol 1-monooxygenase |
DU-145 cell |
malignant prostate cell line |
659814 |
1.14.15.18 | calcidiol 1-monooxygenase |
DU-145 cell |
prostate cancer cell line, greatly decreased activity of 25-hydroxyvitamin D-1alpha-hydroxylase due to decreased RNA transcription |
659943 |
1.14.17.3 | peptidylglycine monooxygenase |
DU-145 cell |
- |
696707, 699036 |
1.14.99.29 | deoxyhypusine monooxygenase |
DU-145 cell |
- |
727927 |
1.2.1.3 | aldehyde dehydrogenase (NAD+) |
DU-145 cell |
- |
686531 |
1.2.1.5 | aldehyde dehydrogenase [NAD(P)+] |
DU-145 cell |
- |
686531 |
1.3.1.1 | dihydropyrimidine dehydrogenase (NAD+) |
DU-145 cell |
- |
685782 |
1.5.1.6 | formyltetrahydrofolate dehydrogenase |
DU-145 cell |
- |
392350 |
1.5.3.13 | N1-acetylpolyamine oxidase |
DU-145 cell |
- |
723916 |
1.5.3.16 | spermine oxidase |
DU-145 cell |
- |
723916 |
2.1.1.100 | protein-S-isoprenylcysteine O-methyltransferase |
DU-145 cell |
- |
720191 |
2.1.1.20 | glycine N-methyltransferase |
DU-145 cell |
- |
734506 |
2.1.1.319 | type I protein arginine methyltransferase |
DU-145 cell |
- |
756861 |
2.3.1.13 | glycine N-acyltransferase |
DU-145 cell |
- |
758269 |
2.3.1.255 | N-terminal amino-acid Nalpha-acetyltransferase NatA |
DU-145 cell |
- |
741089 |
2.3.1.258 | N-terminal methionine Nalpha-acetyltransferase NatE |
DU-145 cell |
- |
740753 |
2.4.1.102 | beta-1,3-galactosyl-O-glycosyl-glycoprotein beta-1,6-N-acetylglucosaminyltransferase |
DU-145 cell |
- |
735617 |
2.4.1.149 | N-acetyllactosaminide beta-1,3-N-acetylglucosaminyltransferase |
DU-145 cell |
- |
706504 |
2.4.1.155 | alpha-1,6-mannosyl-glycoprotein 6-beta-N-acetylglucosaminyltransferase |
DU-145 cell |
- |
690452 |
2.4.1.222 | O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase |
DU-145 cell |
- |
736884 |
2.4.1.69 | type 1 galactoside alpha-(1,2)-fucosyltransferase |
DU-145 cell |
- |
489361, 489363 |
2.4.2.12 | nicotinamide phosphoribosyltransferase |
DU-145 cell |
- |
723576, 735872, 758918 |
2.4.2.28 | S-methyl-5'-thioadenosine phosphorylase |
DU-145 cell |
- |
736923 |
2.4.2.31 | NAD+-protein-arginine ADP-ribosyltransferase |
DU-145 cell |
- |
723565 |
2.4.3.1 | beta-galactoside alpha-(2,6)-sialyltransferase |
DU-145 cell |
- |
759018 |
2.5.1.18 | glutathione transferase |
DU-145 cell |
- |
705056 |
2.5.1.46 | deoxyhypusine synthase |
DU-145 cell |
- |
721265, 737314, 739646 |
2.7.1.105 | 6-phosphofructo-2-kinase |
DU-145 cell |
PFKFB4 is overexpressed in human cancers |
730530 |
2.7.1.91 | sphingosine kinase |
DU-145 cell |
- |
704072 |
2.7.1.94 | acylglycerol kinase |
DU-145 cell |
- |
703034 |
2.7.10.1 | receptor protein-tyrosine kinase |
DU-145 cell |
Ron is highly expressed |
690303 |
2.7.11.10 | IkappaB kinase |
DU-145 cell |
- |
703737 |
2.7.11.11 | cAMP-dependent protein kinase |
DU-145 cell |
- |
708764 |
2.7.11.16 | G-protein-coupled receptor kinase |
DU-145 cell |
- |
737975 |
2.7.11.18 | myosin-light-chain kinase |
DU-145 cell |
- |
709713 |
2.7.11.21 | polo kinase |
DU-145 cell |
- |
760980 |
2.7.11.22 | cyclin-dependent kinase |
DU-145 cell |
CDK5 together with p35 |
679026 |
2.7.11.24 | mitogen-activated protein kinase |
DU-145 cell |
- |
703019, 703255, 740720 |
2.7.7.84 | 2'-5' oligoadenylate synthase |
DU-145 cell |
cell line displays high enzymatic activity |
737800 |
2.8.2.2 | alcohol sulfotransferase |
DU-145 cell |
- |
761662 |
2.8.2.4 | estrone sulfotransferase |
DU-145 cell |
- |
676931 |
3.1.3.16 | protein-serine/threonine phosphatase |
DU-145 cell |
- |
664287 |
3.1.3.66 | phosphatidylinositol-3,4-bisphosphate 4-phosphatase |
DU-145 cell |
- |
752313 |
3.1.3.67 | phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase |
DU-145 cell |
- |
705669 |
3.1.4.11 | phosphoinositide phospholipase C |
DU-145 cell |
- |
670440 |
3.1.4.4 | phospholipase D |
DU-145 cell |
- |
710008 |
3.1.4.54 | N-acetylphosphatidylethanolamine-hydrolysing phospholipase D |
DU-145 cell |
- |
708945 |
3.4.11.2 | membrane alanyl aminopeptidase |
DU-145 cell |
- |
701038 |
3.4.17.1 | carboxypeptidase A |
DU-145 cell |
- |
704669 |
3.4.17.21 | Glutamate carboxypeptidase II |
DU-145 cell |
- |
709812 |
3.4.17.21 | Glutamate carboxypeptidase II |
DU-145 cell |
low expression level |
708256 |
3.4.17.21 | Glutamate carboxypeptidase II |
DU-145 cell |
very low enzyme expression level |
670740 |
3.4.21.109 | matriptase |
DU-145 cell |
- |
683364, 690452, 699127 |
3.4.21.109 | matriptase |
DU-145 cell |
expression determined by quantitative RT-PCR |
707437 |
3.4.21.73 | u-Plasminogen activator |
DU-145 cell |
- |
707983 |
3.4.21.73 | u-Plasminogen activator |
DU-145 cell |
silencing of transmembrane protein Notch1 by siRNA results in significant reduction in the expression of uPA and matrix metalloproteinase-9 gene transcripts. Knock-down of Notch also reduces the mRNA expression and protein levels of uPA and matrix metalloproteinase-9 |
697383 |
3.4.21.77 | semenogelase |
DU-145 cell |
- |
731135 |
3.4.21.77 | semenogelase |
DU-145 cell |
prostate cancer cell, expressing GRP78 on its surface |
717820 |
3.4.21.B25 | PACE4 proprotein convertase |
DU-145 cell |
- |
753401 |
3.4.21.B39 | stratum corneum tryptic enzyme |
DU-145 cell |
- |
707624 |
3.4.21.B6 | prostasin |
DU-145 cell |
- |
652134, 676929 |
3.4.22.15 | cathepsin L |
DU-145 cell |
- |
711400 |
3.4.22.53 | calpain-2 |
DU-145 cell |
- |
709126 |
3.4.22.55 | caspase-2 |
DU-145 cell |
- |
685908 |
3.4.22.55 | caspase-2 |
DU-145 cell |
histone deacetylase inhibition leads to decreased protein kinase casein kinase 2 activity, which is followed by caspase-2 activation and partial cleavage of caspase-8 that sensitizes the tumor cell to TRAIL-induced apoptosis |
684512 |
3.4.22.56 | caspase-3 |
DU-145 cell |
- |
679154 |
3.4.22.60 | caspase-7 |
DU-145 cell |
- |
679154 |
3.4.24.35 | gelatinase B |
DU-145 cell |
- |
717898 |
3.4.24.7 | interstitial collagenase |
DU-145 cell |
- |
708432 |
3.4.24.71 | endothelin-converting enzyme 1 |
DU-145 cell |
expression and localization of the ECE-1 isozymes, overview |
683435 |
3.4.24.80 | membrane-type matrix metalloproteinase-1 |
DU-145 cell |
- |
720437 |
3.4.24.85 | S2P endopeptidase |
DU-145 cell |
- |
733824, 755415 |
3.4.24.86 | ADAM 17 endopeptidase |
DU-145 cell |
- |
734006, 734678 |
3.4.24.B10 | ADAM12 endopeptidase |
DU-145 cell |
androgen-independent prostate cancer cell line |
653225 |
3.4.24.B9 | ADAM9 endopeptidase |
DU-145 cell |
androgen-independent prostate cancer cell line |
653225 |
3.4.25.1 | proteasome endopeptidase complex |
DU-145 cell |
- |
733663 |
3.5.1.2 | glutaminase |
DU-145 cell |
kidney-type glutaminase GLS1 |
720930 |
3.5.1.23 | ceramidase |
DU-145 cell |
- |
719608, 734369, 735103 |
3.5.1.23 | ceramidase |
DU-145 cell |
acid ceramidase is closely associated with malignant progression in human prostate cancer tissues. Acid ceramidase upregulation generates tumor cells that are resistant to normal homeostatic control mechanisms, have an increased number of metastatic characteristics and exhibit resistance to chemotherapy |
685909 |
3.5.1.23 | ceramidase |
DU-145 cell |
prostate cancer cell line |
668638 |
3.5.1.60 | N-(long-chain-acyl)ethanolamine deacylase |
DU-145 cell |
- |
752811 |
3.5.1.88 | peptide deformylase |
DU-145 cell |
- |
675061 |
3.5.1.98 | histone deacetylase |
DU-145 cell |
- |
696716 |
4.1.1.50 | adenosylmethionine decarboxylase |
DU-145 cell |
- |
702137 |
4.2.1.3 | aconitate hydratase |
DU-145 cell |
- |
681864 |
5.1.3.17 | heparosan-N-sulfate-glucuronate 5-epimerase |
DU-145 cell |
- |
727266, 749412 |